R R

What Is Pembrolizumab?

Pembrolizumab is a prescription cancer immunotherapy classified as a programmed death receptor-1, or PD-1, blocking monoclonal antibody. It is marketed as Keytruda for intravenous administration and is approved for several cancers, including selected melanoma, lung, kidney, head and neck, and gastrointestinal cancers. Depending on the diagnosis, pembrolizumab can be prescribed alone or combined with chemotherapy or other cancer treatments. It helps the immune system recognize and attack susceptible cancer cells. Pembrolizumab is not traditional cytotoxic chemotherapy and requires monitoring for serious immune-related adverse reactions.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Pembrolizumab?

Pembrolizumab is a prescription cancer immunotherapy classified as a programmed death receptor-1, or PD-1, blocking monoclonal antibody. It is marketed as Keytruda for intravenous administration and is approved for several cancers, including selected melanoma, lung, kidney, head and neck, and gastrointestinal cancers. Depending on the diagnosis, pembrolizumab can be prescribed alone or combined with chemotherapy or other cancer treatments. It helps the immune system recognize and attack susceptible cancer cells. Pembrolizumab is not traditional cytotoxic chemotherapy and requires monitoring for serious immune-related adverse reactions.

read more about pembrolizumab ...

Copy this HTML:

Copy HTML Copied!

How Does Pembrolizumab Work?

Pembrolizumab binds to PD-1 receptors on immune cells and blocks their interaction with PD-L1 and PD-L2. Some cancer cells use these signaling pathways to reduce the activity of T cells that could otherwise attack them. Blocking PD-1 can restore antitumor immune responses in susceptible cancers. The treatment does not directly kill cancer cells through the same mechanism as conventional chemotherapy. Increased immune activity can also affect healthy organs, creating a risk of inflammation involving the lungs, intestines, liver, kidneys, eyes, and hormone-producing glands.

What Types of Cancer Does Pembrolizumab Treat?

Pembrolizumab has approved indications for selected patients with melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, renal cell carcinoma, and certain colorectal, gastric, esophageal, cervical, endometrial, breast, and other cancers. Some approvals depend on specific biomarkers, including PD-L1 expression, microsatellite instability, mismatch repair deficiency, or high tumor mutational burden. Pembrolizumab can be used in certain early-stage, advanced, or metastatic treatment settings. An oncologist determines eligibility according to cancer type, stage, previous treatment, molecular testing, and the current approved regimen.

How Is Pembrolizumab Administered?

Intravenous pembrolizumab is administered by healthcare professionals, generally over a 30-minute infusion. Common adult single-agent schedules include 200 mg every three weeks or 400 mg every six weeks. Pediatric dosing for approved indications is commonly 2 mg per kilogram every three weeks, up to 200 mg per dose. Some combination regimens have specific schedules or treatment-duration limits. Patients undergo clinical and laboratory monitoring during treatment. Serious immune-mediated adverse effects can require dose withholding, corticosteroid treatment, or permanent discontinuation. Separate subcutaneous pembrolizumab-containing products have different administration instructions.

What Are the Side Effects and Warnings of Pembrolizumab?

Common adverse effects include fatigue, rash, itching, diarrhea, nausea, and musculoskeletal pain. Serious immune-mediated reactions can cause pneumonitis, colitis, hepatitis, kidney inflammation, endocrine disorders, and ocular inflammation. Some complications can be life-threatening and can develop during treatment or after it ends. Pembrolizumab can also cause infusion reactions, complications following certain stem cell transplants, and fetal harm. Clinicians monitor symptoms and laboratory findings throughout treatment. New breathing difficulties, persistent diarrhea, jaundice, severe weakness, or changes in vision require prompt medical assessment.

Common Questions About Pembrolizumab

Is pembrolizumab the same as Keytruda?

Yes. Keytruda is the brand name for intravenous pembrolizumab, a PD-1-blocking immunotherapy used for selected cancers.

Is pembrolizumab a chemotherapy medication?

No. Pembrolizumab is an immune checkpoint inhibitor. It works differently from traditional chemotherapy, although the two treatments can be combined for certain cancers.

How often is pembrolizumab administered?

Common adult intravenous schedules include 200 mg every three weeks or 400 mg every six weeks. Other schedules apply to certain pediatric patients and combination regimens.

Can pembrolizumab cause vision problems?

Yes. Pembrolizumab can cause immune-related eye inflammation, including uveitis. New eye pain, redness, light sensitivity, or visual changes require prompt assessment.

References

DailyMed - KEYTRUDA (pembrolizumab) injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287. Date Accessed October 30, 2026.

Keytruda. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda. Date Accessed October 30, 2026.

Pembrolizumab. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548050/. Date Accessed October 30, 2026.

Pembrolizumab. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab. Date Accessed October 30, 2026.

Pembrolizumab Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a614048.html. Date Accessed October 30, 2026.